六味地黃丸與降脂方治療高血脂症之臨床療效評估

Clinical Efficacy Evaluation on Lipid-Lowering Effect of Liuwei Dihuang Wan and Lipid-Lowering-Tea

蔡敏鈴(Min-Ling Tsai) ； 李建瑩(Chien-Ying Lee) ； 施宏哲(Hung-Che Shih) ； 張宏州(Hung-Chou Chang)

《台灣中醫臨床醫學雜誌》 17卷2期 (2011/06) Pp. 116-126

https://doi.org/10.6968/TJCCM.201106.0116

摘要

Hyperlipidemia is a common metabolic disease, which is the important factor of coronary artery disease as well as cerebrovascular disease. This study selects 2 documented effective Chinese medicine formulas for hyperlipidemia-”Liuwei Dihuang Wan” and ”Lipid-Lowering-Tea”. The aim of this study is to evaluate the clinical efficacy on cholesterol-lowering effect of the two prescriptions. This study is an open, randomized, parallel clinical trial. We screened and rerolled 40 participants with hyperlipidemia. After signature of the informed consent form, these participants were randomized assigned to 2 different groups for hyperlipidemia treatment for 8 weeks. ”Liuwei Dihuang Wan” group showed the potential to reduce lower-density lipoprotein cholesterol (LDL-C) and triglyceride (TG), but all have not reached the remarkable significance. ”Lipid-Lowering-Tea” group showed the tendency to level down TG, but not LDL-C, and all have not reached the remarkable significance. The above 2 prescriptions showed the efficacy to lower body weight and BMI, and statistics showed remarkable significance, p-value ＜ 0.05. Besides, after the 8 weeks treatment, all the patients' liver and renal function is intact, which showed the safety of the 2 prescriptions. This study showed the tendency of the lipid-lowering effect of the ”Liuwei Dihuang Wan” and ”Lipid-Lowering-Tea”. We expect the further randomized, double-blinded, study to evaluate the efficacy of Chinese Medicine.

關鍵字

六味地黃丸 ； 降脂方 ； 低密度脂蛋白膽固醇 ； 三酸甘油脂

並列摘要

Hyperlipidemia is a common metabolic disease, which is the important factor of coronary artery disease as well as cerebrovascular disease. This study selects 2 documented effective Chinese medicine formulas for hyperlipidemia-”Liuwei Dihuang Wan” and ”Lipid-Lowering-Tea”. The aim of this study is to evaluate the clinical efficacy on cholesterol-lowering effect of the two prescriptions. This study is an open, randomized, parallel clinical trial. We screened and rerolled 40 participants with hyperlipidemia. After signature of the informed consent form, these participants were randomized assigned to 2 different groups for hyperlipidemia treatment for 8 weeks. ”Liuwei Dihuang Wan” group showed the potential to reduce lower-density lipoprotein cholesterol (LDL-C) and triglyceride (TG), but all have not reached the remarkable significance. ”Lipid-Lowering-Tea” group showed the tendency to level down TG, but not LDL-C, and all have not reached the remarkable significance. The above 2 prescriptions showed the efficacy to lower body weight and BMI, and statistics showed remarkable significance, p-value ＜ 0.05. Besides, after the 8 weeks treatment, all the patients' liver and renal function is intact, which showed the safety of the 2 prescriptions. This study showed the tendency of the lipid-lowering effect of the ”Liuwei Dihuang Wan” and ”Lipid-Lowering-Tea”. We expect the further randomized, double-blinded, study to evaluate the efficacy of Chinese Medicine.

並列關鍵字

Liuwei Dihuang Wan ； Lipid-Lowering-Tea ； hyperlipidemia